Ignite Creation Date:
2025-12-24 @ 5:28 PM
Ignite Modification Date:
2026-01-27 @ 1:03 AM
Study NCT ID:
NCT05546268
Status:
RECRUITING
Last Update Posted:
2025-10-22
First Post:
2022-09-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Oral MRT-2359 in Selected Cancer Patients
Sponsor:
Monte Rosa Therapeutics, Inc
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | NSCLC | View |
| None | SCLC | View |
| None | High Grade Neuroendocrine Cancer | View |
| None | DLBCL | View |
| None | L-MYC and N-MYC Amplified Solid Tumors | View |
| None | NSCLC With High or Low L-MYC or N-MYC Expression | View |
| None | HR-positive, HER2-negative Breast Cancer | View |
| None | Prostate Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Small Cell Lung Cancer | View |
| None | Non-Small Cell Lung Cancer | View |
| None | L-MYC Amplification | View |
| None | N-MYC Amplification | View |
| None | L-MYC expression | View |
| None | N-MYC expression | View |
| None | High-grade neuroendocrine | View |
| None | Diffuse Large B-Cell Lymphoma | View |
| None | Molecular glue degrader | View |
| None | Anti-tumor | View |
| None | GSPT1 | View |
| None | HR-positive | View |
| None | HER2-negative | View |
| None | Breast Cancer | View |
| None | Prostate Cancer | View |